Teachers Advisors LLC Boosts Holdings in Jounce Therapeutics (JNCE)

Teachers Advisors LLC raised its stake in Jounce Therapeutics (NASDAQ:JNCE) by 59.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 25,542 shares of the company’s stock after buying an additional 9,507 shares during the period. Teachers Advisors LLC owned approximately 0.08% of Jounce Therapeutics worth $326,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of JNCE. Rhumbline Advisers bought a new position in shares of Jounce Therapeutics in the fourth quarter valued at $134,000. American International Group Inc. increased its holdings in shares of Jounce Therapeutics by 132.2% in the third quarter. American International Group Inc. now owns 9,559 shares of the company’s stock valued at $149,000 after buying an additional 5,442 shares in the last quarter. Paloma Partners Management Co bought a new position in shares of Jounce Therapeutics in the fourth quarter valued at $230,000. SG Americas Securities LLC bought a new position in shares of Jounce Therapeutics in the fourth quarter valued at $294,000. Finally, Swiss National Bank increased its holdings in shares of Jounce Therapeutics by 84.3% in the fourth quarter. Swiss National Bank now owns 24,700 shares of the company’s stock valued at $315,000 after buying an additional 11,300 shares in the last quarter. 90.11% of the stock is currently owned by institutional investors.

NASDAQ JNCE opened at $19.46 on Monday. The firm has a market capitalization of $631.73, a price-to-earnings ratio of -34.14 and a beta of 6.33. Jounce Therapeutics has a 1 year low of $11.05 and a 1 year high of $29.29.

Jounce Therapeutics (NASDAQ:JNCE) last posted its quarterly earnings results on Thursday, March 8th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.59) by $0.25. The company had revenue of $13.00 million for the quarter, compared to analysts’ expectations of $14.95 million. Jounce Therapeutics had a negative return on equity of 10.24% and a negative net margin of 22.76%. The firm’s revenue was down 36.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.05 earnings per share. equities research analysts forecast that Jounce Therapeutics will post -1.04 EPS for the current fiscal year.

In other Jounce Therapeutics news, Director Barbara Gayle Duncan sold 4,000 shares of the business’s stock in a transaction on Friday, January 26th. The shares were sold at an average price of $25.00, for a total transaction of $100,000.00. Following the sale, the director now directly owns 4,000 shares of the company’s stock, valued at approximately $100,000. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Richard /Ca/ Murray sold 16,334 shares of the business’s stock in a transaction on Monday, March 5th. The shares were sold at an average price of $21.43, for a total transaction of $350,037.62. Following the sale, the chief executive officer now directly owns 16,334 shares in the company, valued at $350,037.62. The disclosure for this sale can be found here. Over the last three months, insiders have sold 58,292 shares of company stock worth $1,372,403.

Several research analysts have issued reports on JNCE shares. Zacks Investment Research raised Jounce Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a report on Wednesday, January 3rd. Robert W. Baird set a $35.00 price target on Jounce Therapeutics and gave the company a “buy” rating in a report on Thursday, March 8th.

TRADEMARK VIOLATION NOTICE: This story was posted by Week Herald and is the sole property of of Week Herald. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://weekherald.com/2018/04/23/teachers-advisors-llc-boosts-holdings-in-jounce-therapeutics-jnce.html.

About Jounce Therapeutics

Jounce Therapeutics, Inc, a clinical stage immunotherapy company, develops therapies for the treatment of cancer. Its lead product candidate is JTX-2011, a clinical stage monoclonal antibody that binds to and activates the inducible T cell co-stimulator, a protein on the surface of certain T cells found in solid tumors, which is in Phase I/II clinical trial for the treatment of six tumor types, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, gastric cancer, and other tumor types identified through its translational science platform.

Want to see what other hedge funds are holding JNCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jounce Therapeutics (NASDAQ:JNCE).

Institutional Ownership by Quarter for Jounce Therapeutics (NASDAQ:JNCE)

Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply